Pharming Announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST(R) for Prophylaxis of Hereditary Angioedema Attacks

LEIDEN, Netherlands, January 17, 2018 -- (Healthcare Sales & Marketing Network) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) announced today that the U.S. Food and Drug Administration (FDA) has accep... Biopharmaceuticals Pharming Group, RUCONEST, hereditary angioedema

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2043406

Source: HSMN NewsFeed - January 17, 2018 Category: Pharmaceuticals Source Type: news

More News: Food and Drug Administration (FDA) | Marketing | Netherlands Health | Pharmaceuticals